Update on breast cancer risk prediction and prevention

Current Opinion in Obstetrics and Gynecology

Volumn 27, Issue 1, 2015, Pages 92-97

  Sestak, Ivana ^a   Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

aromatase inhibitors; breast cancer; prevention; risk prediction; tamoxifen

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ACETYLSALICYLIC ACID; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; BREAST DENSITY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; FEMALE; HUMAN; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST NEOPLASMS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ONSET AGE; TREATMENT OUTCOME;

AGE OF ONSET; AROMATASE INHIBITORS; ASPIRIN; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; METFORMIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84920807363     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000153     Document Type: Review

References (68)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: cancer incidence mortality and prevalence worldwide. Lyon, France: IARC Press; 2002.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: IARC Press; 2013.
3. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
4. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breastconserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011; 378:1707-1716.
5. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771-784.
6. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005; 23:1636-1643.
7. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356:2388-2398.
8. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886.
9. Corbelli J, Borrero S, Bonnema R, et al. Use of the Gail model and breast cancer preventive therapy among three primary care specialties. J Womens Health (Larchmt) 2014; 23:746-752.
10. Amir E, Freedman O. Underestimation of risk by Gail model extends beyond women with atypical hyperplasia. J Clin Oncol 2009; 27:1526.
11. Boyd NF, Lockwood GA, Byng JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7:1133-1144.
12. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011; 13:223.
13. Timmers JM, Verbeek AL, IntHout J, et al. Breast cancer risk prediction model: a nomogram based on common mammographic screening findings. Eur Radiol 2013; 23:2413-2419.
14. Brentnall AR, Evans DG, Cuzick J. Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. Br J Cancer 2014; 110:827-828.
15. Cuzick J, Brentnall AR, Segala C, et al. Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: results from two randomized tamoxifen prevention trials. J Clin Oncol 2014; 32 (5s); Suppl; abstr 1519.
16. Darabi H, Czene K, Zhao W, et al. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 2012; 14:R25.
17. Tworoger SS, Zhang X, Eliassen AH, et al. Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol 2014; 2014:3111-3117.
18. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381:1827-1834.
19. National Institute for Health and Care Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. London, UK: NICE; 2013.
20. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
21. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23:5138-5147.
22. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-492.
23. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
24. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
25. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
26. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28:509-518.
27. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381-2391.
28. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014; 383:1041-1048.
29. Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33:1304-1308.
30. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012; 30:2844-2852.
31. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55:654-665.
32. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3:1451-1461.
33. Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188-197.
34. Zhu P, Davis M, Blackwelder AJ, et al. Metformin selectively targets tumorinitiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) 2014; 7:199-210.
35. Thompson AM. Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res 2014; 20:2508-2515.
36. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012; 30:2593-2600.
37. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128:783-794.
38. Kalinsky K, Crew KD, Refice S, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 2014; 32:150-157.
39. Cazzaniga M, DeCensi A, Pruneri G, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013; 109:2792-2797.
40. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014; 16:746-752.
41. Campagnoli C, Berrino F, Venturelli E, et al. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 2013; 13:433-438.
42. Goodwin PJ, Stambolic V, Lemieux J, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anticancer agents. Breast Cancer Res Treat 2011; 126:215-220.
43. Kim J, Lim W, Kim EK, et al. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer 2014; 14:170.
44. Goss PE, Hershman DL, Cheung AM, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol 2014; 15:474-482.
45. Winter MC, Coleman RE. Bisphosphonates in the adjuvant treatment of breast cancer. Clin Oncol (R Coll Radiol) 2013; 25:135-145.
46. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010; 28:3577-3581.
47. Chlebowski RT, Col N. Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 2012; 12:144-150.
48. Gnant M, Blaha P, Dubsky P, et al. Adjuvant bisphosphonates in endocrineresponsive breast cancer: what is their place in therapy? Ther Adv Med Oncol 2009; 1:123-136.
49. Hue TF, Cummings SR, Cauley JA, et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 2014; 174:1550-1557.
50. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2014.
51. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28:1467-1472.
52. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13:518-527.
53. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23:1403-1415.
54. Li Y, Brasky TM, Nie J, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2012; 21:239-242.
55. Wald NJ, Morris JK, Law MR. Aspirin in the prevention of cancer. Lancet 2011; 377:1649.
56. Ralph AF, Ager B, Bell ML, et al. Womens preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory. Patient Educ Couns 2014; 96:106-112.
57. Peres J. Why is breast cancer chemoprevention such a hard sell? J Natl Cancer Inst 2014; 106:; dju139.
58. Peto R, Collins R, Sackett D, et al. The Trials of Dr. Bernard Fisher: a European perspective on an American episode controlled clinical trials 1997; 18:1-13.
59. Rennie D. Breast cancer: how to mishandle misconduct. J Am Med Assoc 1994; 271:1205-1207.
60. Angel M, Kassirer JP. Setting the record straight in the breast cancer trials. N Eng J Med 1994; 330:1448-1450.
61. Rahme E, Ghosn J, Dasgupta K, et al. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005; 5:159.
62. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6:27.
63. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006; 94:346-350.
64. Eliassen AH, Colditz GA, Rosner B, et al. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005; 165:2264-2271.
65. Esserman LJ, Campbell M, Shoemaker M. Breast cancer inhibition by statins. Proc Am Soc Clin Oncol 2004; 23:97.
66. Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103:744-752.
67. Kim J, Han W, Moon HG, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012; 14:R102.
68. Li J, Humphreys K, Eriksson L, et al. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 2013; 31:2249-2256.